157 related articles for article (PubMed ID: 31336472)
21. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus.
Wang QY; Chen FQ
Diabetes Res Clin Pract; 2009 Feb; 83(2):215-9. PubMed ID: 19097668
[TBL] [Abstract][Full Text] [Related]
22. Circulating ApoE level is independently associated with urinary albumin excretion in type 2 diabetic patients.
Ling Y; Li X; Gu Q; Gao X
Intern Med; 2011; 50(24):2961-6. PubMed ID: 22185986
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biochemical features of type 2 diabetic patients in Gaza Governorate, Gaza Strip.
Yassin MM; Altibi HI; Elshanti AF
West Afr J Med; 2011; 30(1):51-6. PubMed ID: 21863590
[TBL] [Abstract][Full Text] [Related]
24. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
25. Studies of cardiovascular and renal function in subclinical and manifest diabetic nephropathy.
Berglund J
Acta Med Scand Suppl; 1988; 722():1-69. PubMed ID: 3163465
[TBL] [Abstract][Full Text] [Related]
26. Hypomagnesaemia: a modifiable risk factor of diabetic nephropathy.
Bherwani S; Jibhkate SB; Saumya AS; Patel SK; Singh R; Ghotekar LH
Horm Mol Biol Clin Investig; 2017 Mar; 29(3):79-84. PubMed ID: 27416617
[TBL] [Abstract][Full Text] [Related]
27. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.
Shoukry A; Bdeer Sel-A; El-Sokkary RH
Mol Cell Biochem; 2015 Oct; 408(1-2):25-35. PubMed ID: 26104579
[TBL] [Abstract][Full Text] [Related]
28. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.
Gall MA; Nielsen FS; Smidt UM; Parving HH
Diabetologia; 1993 Oct; 36(10):1071-8. PubMed ID: 8243857
[TBL] [Abstract][Full Text] [Related]
29. Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes.
Wen J; Yuan H
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3198. PubMed ID: 31228226
[TBL] [Abstract][Full Text] [Related]
30. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
31. Adipokine zinc-alpha-2-glycoprotein as a novel urinary biomarker presents earlier than microalbuminuria in diabetic nephropathy.
Wang Y; Li YM; Zhang S; Zhao JY; Liu CY
J Int Med Res; 2016 Apr; 44(2):278-86. PubMed ID: 26857862
[TBL] [Abstract][Full Text] [Related]
32. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy.
Karatas A; Turkmen E; Erdem E; Dugeroglu H; Kaya Y
Biomark Med; 2018 Sep; 12(9):953-959. PubMed ID: 30043636
[TBL] [Abstract][Full Text] [Related]
33. Cystatin-C and TGF-β levels in patients with diabetic nephropathy.
Takir M; Unal AD; Kostek O; Bayraktar N; Demirag NG
Nefrologia; 2016; 36(6):653-659. PubMed ID: 27745866
[TBL] [Abstract][Full Text] [Related]
34. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
[TBL] [Abstract][Full Text] [Related]
35. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus.
Dejenie TA; Abebe EC; Mengstie MA; Seid MA; Gebeyehu NA; Adella GA; Kassie GA; Gebrekidan AY; Gesese MM; Tegegne KD; Anley DT; Feleke SF; Zemene MA; Dessie AM; Moges N; Kebede YS; Bantie B; Adugna DG
Front Endocrinol (Lausanne); 2023; 14():1124367. PubMed ID: 37082121
[TBL] [Abstract][Full Text] [Related]
36. Glycemic status, lipid profile and proteinuria in diabetic nephropathy.
Jha P; Das BK; Shrestha S; Majhi S; Chandra L; Sharma S; Baral N
JNMA J Nepal Med Assoc; 2010; 49(178):143-6. PubMed ID: 21485601
[TBL] [Abstract][Full Text] [Related]
37. Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients.
Tseng CH
Kidney Int; 2005 Apr; 67(4):1547-53. PubMed ID: 15780110
[TBL] [Abstract][Full Text] [Related]
38. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A.
Kacso IM; Bondor CI; Kacso G
Clin Biochem; 2012 Nov; 45(16-17):1415-20. PubMed ID: 22836100
[TBL] [Abstract][Full Text] [Related]
39. Decreased serum myonectin concentrations in diabetic nephropathy patients.
Zhang J; Hu W; Lin P; Wang R
Clin Exp Med; 2020 Nov; 20(4):601-607. PubMed ID: 32852729
[TBL] [Abstract][Full Text] [Related]
40. Association Between Matrix Metalloproteinase-3 Activity and Glomerular Filtration Rate and Albuminuria Status in Patients With Type 2 Diabetes Mellitus.
Amanzadeh M; Mota A; Zarghami N; Abedi-Azar S; Abroon S; Akbarian N; Mihanfar A; Rahmati-Yamchi M
Iran J Kidney Dis; 2018 Jan; 12(1):40-47. PubMed ID: 29421776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
